Literature DB >> 26819202

Cutting Edge: The RIG-I Ligand 3pRNA Potently Improves CTL Cross-Priming and Facilitates Antiviral Vaccination.

Katharina Hochheiser1, Marika Klein2, Catherine Gottschalk2, Florian Hoss2, Stefanie Scheu3, Christoph Coch4, Gunther Hartmann4, Christian Kurts1.   

Abstract

Protective immunity against intracellular pathogens involves the induction of robust CTL responses. Vaccination with protein Ags establishes such responses only when combined with immune-stimulatory adjuvants. In this study, we compared different adjuvants and identified triphosphate RNA (3pRNA) as especially effective at inducing CTL responses. 3pRNA sensing required IPS-1/MAVS signaling and induced type I IFN in plasmacytoid dendritic cells and macrophages, with the latter being more important for the adjuvant effect. Type I IFN acted on CD11c(+) cells, especially on CD8α(+) Batf3-dependent dendritic cells. Vaccination with OVA in combination with 3pRNA protected mice from a subsequent OVA-encoding adenovirus infection in a CD8(+) cell-dependent manner and more efficiently than other adjuvants. In summary, 3pRNA is a superior adjuvant for CTL activation and might be useful to facilitate antiviral immunization strategies.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26819202     DOI: 10.4049/jimmunol.1501958

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways.

Authors:  Alessandra Zevini; David Olagnier; John Hiscott
Journal:  Trends Immunol       Date:  2017-01-07       Impact factor: 16.687

2.  DAMP-driven metabolic adaptation.

Authors:  Kirsty Minton
Journal:  Nat Rev Immunol       Date:  2020-01       Impact factor: 53.106

Review 3.  Regulation of the Cell Biology of Antigen Cross-Presentation.

Authors:  J Magarian Blander
Journal:  Annu Rev Immunol       Date:  2018-02-28       Impact factor: 28.527

4.  Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses.

Authors:  Céline Cousin; Marine Oberkampf; Tristan Felix; Pierre Rosenbaum; Robert Weil; Sylvie Fabrega; Valeria Morante; Donatella Negri; Andrea Cara; Gilles Dadaglio; Claude Leclerc
Journal:  Cell Rep       Date:  2019-01-29       Impact factor: 9.423

Review 5.  Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.

Authors:  Shetal A Patel; Andy J Minn
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

6.  Intranasal Delivery of RIG-I Agonist Drives Pulmonary Myeloid Cell Activation in Mice.

Authors:  Sajith Nair; Yilun Wu; Trinh Mai Nguyen; Katja Fink; Dahai Luo; Christiane Ruedl
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 7.  The comings and goings of MHC class I molecules herald a new dawn in cross-presentation.

Authors:  J Magarian Blander
Journal:  Immunol Rev       Date:  2016-07       Impact factor: 12.988

8.  TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination.

Authors:  Randall Toy; M Cole Keenum; Pallab Pradhan; Katelynn Phang; Patrick Chen; Chinwendu Chukwu; Lily Anh H Nguyen; Jiaying Liu; Sambhav Jain; Gabrielle Kozlowski; Justin Hosten; Mehul S Suthar; Krishnendu Roy
Journal:  J Control Release       Date:  2020-11-05       Impact factor: 9.776

Review 9.  Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.

Authors:  John J Suschak; James A Williams; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

10.  A minimal RNA ligand for potent RIG-I activation in living mice.

Authors:  Melissa M Linehan; Thayne H Dickey; Emanuela S Molinari; Megan E Fitzgerald; Olga Potapova; Akiko Iwasaki; Anna M Pyle
Journal:  Sci Adv       Date:  2018-02-21       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.